Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients.

MLA

McCormick, Adele L., et al. “Baseline Drug Resistance Mutations Are Detectable in HCV Genes NS3 and NS5A but Not NS5B in Acute and Chronic HIV-Coinfected Patients.” Antiviral Therapy, vol. 20, no. 3, 2015, pp. 361–63. EBSCOhost, https://doi.org/10.3851/IMP2871.

APA

McCormick, A. L., Moynihan, L., Macartney, M. J., Garcia-Diaz, A., Smith, C., Johnson, M. A., Rodger, A. J., Bhagani, S., Haque, T., & Webster, D. P. (2015). Baseline drug resistance mutations are detectable in HCV genes NS3 and NS5A but not NS5B in acute and chronic HIV-coinfected patients. Antiviral Therapy, 20(3), 361–363. https://doi.org/10.3851/IMP2871

Chicago

McCormick, Adele L, Luke Moynihan, Malcolm J Macartney, Ana Garcia-Diaz, Colette Smith, Margaret A Johnson, Alison J Rodger, Sanjay Bhagani, Tanzina Haque, and Daniel P Webster. 2015. “Baseline Drug Resistance Mutations Are Detectable in HCV Genes NS3 and NS5A but Not NS5B in Acute and Chronic HIV-Coinfected Patients.” Antiviral Therapy 20 (3): 361–63. doi:10.3851/IMP2871.